The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, has reiterated its bullish view on ImmuPharma.
a pharmaceutical development company that develops novel medicines, in specialist markets with serious unmet needs, is currently focused on developing its lead asset addressing Lupus: Lupuzor.
The Life Sciences Division, in a note to investors, commented on’s Anifrolumab and its navigation through a Phase III lupus clinical trial, alluding to the potential of AIM listed ImmuPharma’s LupuzorTM.
Dr. Navid Malik, Head of Life Sciences Research at TLSD, said in a research note: "Lupus still represents a major area of unmet medical need and there is a strong need for safe and efficacious products.”
Dr. Navid adds: “We believe that the recent update for Anifrolumab is positive for the Lupus field, but also reminds us that LupuzorTM could represent a highly successful product if it successfully navigates a second Phase III clinical trial.”
“Now that we understand the target patient group of Lupus patients who respond best to the drug, we see the path to market as being de-risked."
Shares in ImmuPharma fell dramatically after its Phase III Trial last April failed to meet its primary endpoint, but confirmed the safety profile of Lupuzor™, with zero serious adverse events reported.
The fact that Lupuzor is a late stage asset, with a “unique mechanism of action", The Life Sciences Division view it as an important potential treatment for Lupus patients.
Pharmaceutical investors will be closely following the data published from AstraZeneca’s TULIP II study and its implications..
Follow News & Updates from ImmuPharma here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Next is ‘weathering the retail storm’ as it enjoyed a rise in half-year profits, the store’s boss revealed, The competition watchdog said JD Sports £90m takeover of Footasylum could lead to “higher prices” and “worse choice” for shoppers, but fell short of explaining its reasons in more detail
Travel firm Thomas Cook has been hit with a last-minute demand, from its banks, to find £200m in extra funding in order to secure its future. The troubled operator hoped to seal a rescue deal this week but without this, the firm is likely to collapse.
Salt Lake Potash explain the significance of producing premium grade water soluble sulphate Of potash from its Lake Way Project. Iconic Labs discuss their strategy and recent deals. Chris Bailey on Next, Diageo & Johnson Matthey. John Meyer on Kodal Minerals, Arc Minerals & BlueJay Mining.
SP Angel research note on commodities and miners, featuring: Asiamet Resources (ARS LN) - Logistics enhancements Bushveld Minerals* (BMN LN) BUY – Valuation 92p – Conference presentation in South Africa highlights forecast growth of vanadium electrolyte demand Kodal Minerals* (KOD LN) - ESIA Progress Report IronRidge Resources* (IRR LN) - Aircore results from Cote d'Ivoire Ironveld (IRON LN) – NED director resignation Solgold* (SOLG LN) - Constitutional Court ruling in Ecuador
The main trade union at Royal Mail has served notice for a strike ballot among 110,000 workers, Hong Kong is under growing pressure to sweeten the terms of its £32bn offer for the London Stock Exchange Group as a takeover battle for the British bourse intensifies
The US central bank has cut interest rates for only the second time since 2008, amid concerns about slowing global growth and trade wars. As expected the Federal Reserve lowered the target range for its key interest rate by 25 basis points to between 1.75% and 2%.